Miejski Szpital Zespolony W Olsztynie — Clinical Trial Site

15 Registered trials

3 Currently recruiting

Organisation

Miejski Szpital Zespolony W Olsztynie

Location

Olsztyn, Poland

Identifier

ORG-100049355

Address

Ul. Niepodleglosci 44, 10-045, Poland

Departments

#1651:Klinika Dermatologii Chorób Przenoszonych Drogą Płciową i Immunologii Klinicznej
#5705:Klinika Dermatologii
Dermatology
Dermatology, Sexually Transmitted Diseases and Clinical Immunology Clinic
Klinika Dermatologii, Chorob Przenoszonych Droga Plciowa i Immunologii Klinicznej
Klinika Dermatologii, Chorób Przenoszonych Drogą Płciową i Immunologii Klinicznej
Klinika Kardiologii i Chorób Wewnętrznych
N/A

Clinical trials at this site (15)

Search interface

A Phase 2 Study of the Effects and Safety of PF-07328948 in Adults with Heart Failure (BRANCH-HF) Recruiting

2024-518438-94-00 Heart failure 4 2025-10-24
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum Recruiting

2024-514306-31-00 Pyoderma gangrenosum 5 2025-02-13
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata Patients (Rezolve AA) Ended

2023-509981-39-00 Alopecia Areata 4 2024-11-20
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy,… Ended

2023-505739-12-01 Chronic Inducible Urticaria (CINDU) 5 2024-09-30
A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended

2023-503692-24-00 Cutaneous Lupus Erythematosus 5 2024-09-25
A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended

2024-514502-31-00 Prurigo Nodularis 5 2021-01-11
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511363-28-00 hidradenitis suppurativa (HS) 5 2024-09-24
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended

2022-501196-41-00 Dermatitis atopic 5 2024-05-29
A Phase 2 Study of the Effects of Ponsegromab on Health-Related Quality of Life and Safety in Patients With Heart Failure (GARDEN-TIMI 74) Ended

2023-509747-27-00 Heart failure 4 2023-05-18
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68) Ended

2024-517612-29-00 acute heart failure 11 2023-02-14
Pulmonary REsistance modification under treatment with Sacubitil/valsartaN in paTients with HeartFailure with reduced ejection fraction Ended

2024-517975-19-00 Heart Failure with reduced ejection fraction. 6 2022-12-12
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12